Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4

Benzinga Newsdesk www.benzinga.com Neutral 61.2%

Neg 0% Neu 61.2% Pos 0%

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Overweight rating and announces Price Target of $4.